GlassScriptPhysician profile
Imran M Malik
NPI 1760651285
$2,040.93
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $279 · 2021: $411 · 2022: $376 · 2023: $64.17 · 2024: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $287.96 | 2019-2022 | |
| Glaxosmithkline, LLC. | $193.89 | 2019-2024 | Trelegy Ellipta |
| Pfizer INC. | $190.61 | 2019-2024 | |
| Novo Nordisk INC | $172.80 | 2019-2024 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $157.50 | 2019-2024 | Airsupra |
| Abbvie INC. | $138.19 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $108.46 | 2019-2022 | |
| Abbott Laboratories | $103.44 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $97.46 | 2019 | |
| Avanir Pharmaceuticals, INC. | $89.99 | 2021 | |
| Amarin Pharma, INC. | $75.25 | 2019-2021 | |
| Neurelis, INC. | $58.47 | 2022 | |
| Amgen INC. | $51.36 | 2021-2024 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $47.38 | 2019 | |
| Biogen, INC. | $36.61 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.78 | 2020-2024 | Xifaxan |
| Hologic Sales and Service, LLC | $24.94 | 2023 | Thinprep 2000 Processor, Aptima |
| Xeris Pharmaceuticals, INC. | $23.71 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.48 | 2021 | |
| Neurocrine Biosciences, INC. | $21.02 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.38 | 2022 | |
| Medtronic, INC. | $19.78 | 2022 | |
| Allergan, INC. | $19.51 | 2019 | |
| Dexcom, INC. | $18.54 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.08 | 2019 | |
| Lilly USA, LLC | $13.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.